AAD VMX 2021: Bimekizumab Shows Superior Efficacy Over Secukinumab in Treatment of Psoriasis
Benefits may be due to inhibition of both interleukin 17A and 17F
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.